GLP-1 agonists have transformed the treatment of type 2 diabetes and obesity, but they come with side effects. Physicians say the benefits outweigh the risks.
Sagimet’s denifanstat delivered significant improvements in disease activity and fibrosis for patients with metabolic dysfunction-associated steatohepatitis.
Paolo Martini leads the biotech company’s rare disease research program with the hope of developing the very first treatments for genetic metabolic disorders.
Scientists have appreciated the roles of bacteria in our microbiomes for decades. Now, they’re studying the effects of the trillions of viruses that call the human body home.
High resolution microscopy revealed distinct mitochondrial populations in inner ear hair cells, setting the stage for probing their role in mitochondrial deafness.